Immunological Effects Following Administration of Interferon-α in Patients with Chronic Hepatitis C Virus (cHCV) Infection

References

• Alter M. J., Margolis H. S., Krawczynski K., et al. The natural history of community acquired hepatitis C in the United States. New Engl. J. Med. 1992; 327: 1899
   PubMed Web of Science ®Google Scholar
• Jirillo E., Greco B., Caradonna L., et al. Evaluation of cellular responses and soluble mediators in patients with chronic hepatitis C virus (cHCV) infection. Immunopharm. Immunot. 1995; 17: 347
   PubMed Web of Science ®Google Scholar
• Tilg H., Wilmer A., Vogel W., et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264
   PubMed Web of Science ®Google Scholar
• Smith C. A., Farrah T., Goodwin R. G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 1994; 76: 959
   PubMed Web of Science ®Google Scholar
• Muller C., Knoflach P., Zielinski C. C. Soluble interleukin 2 receptor in acute viral hepatitis and chronic liver disease. Hepatology 1989; 10: 928
   PubMed Web of Science ®Google Scholar
• Adams D. H., Mainolfi E., Burra P., et al. Detection of circulating intercellular adhesion molecule-1 in chronic liver diseases. Hepatology 1992; 16: 810
   PubMed Web of Science ®Google Scholar
• Zohrens G., Armbrust T., Pirzer U., et al. Intercellular adhesion molecule-1 concentration in sera of patients with acute and chronic her disease: relationship to disease activity and cirrhosis. Hepatology 1993; 18: 798
   PubMed Web of Science ®Google Scholar
• Symons J. A., Wood N. C., Di Giovine F. S., et al. Soluble IL-2 receptor in rheumatoid arthritis: correlation with disease activity, IL-1 and IL-2 inhibition. J. Immunol. 1988; 141: 2612
   PubMed Web of Science ®Google Scholar
• Barton D. P.J., Blanchard D. K., Michelini-Norris B., et al. Serum soluble interleukin-2 receptor α levels in patients with gynecological cancers: early effect of surgery. Am. J. Reprod. Immunol. 1993; 30: 202
   PubMedGoogle Scholar
• Van Deventer S. J.H., Ten Cate J. W., Tytgat G. N.J. Intestinal endotoxinemia:clinical significance. Gastroenterology 1988; 94: 825
   PubMed Web of Science ®Google Scholar
• Danner R. L., Elin R. J., Hosseini J. M., et al. Endotoxaemia in human septic shock. Chest 1991; 99: 169
   PubMed Web of Science ®Google Scholar
• Oesterreicher C., Pfeffel F., Petermann D., et al. Increased in vitro production and serum levels of the soluble lipopolysaccharide receptor sCD14 in liver disease. J. Hepatol. 1995; 23: 396
   PubMed Web of Science ®Google Scholar
• Steinmann G. G., Rosenkamer F., Leitz G. Clinical experiences with interferon-α and interferon-γ. Int. Rev. Ex. Pathol. 1993; 34B: 193
   Google Scholar
• Dianzani F. Interferon toxicity. A mechanistic view. Trends Ex. Clin. Med. 1995; 4: 397
   Google Scholar
• Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Inv. 1968; 21(suppl. 97)77
   PubMed Web of Science ®Google Scholar
• Mandell L., Hook W. E. Leukocyte function in chronic granulomatous diseases of childhood. Am. J. Med. 1969; 47: 473
   PubMed Web of Science ®Google Scholar
• Antonaci S., Tortorella C., De Simone C., et al. Role of bacterial lipopolysaccharides in the development of natural antibacterial activity mediated by human peripheral blood T lymphocytes. Int. Rev. Immunol. 1990; 6: 237
   PubMedGoogle Scholar
• Wejstal R. Immune-mediated liver damage in chronic hepatitis C. Scand. J. Gastroenterol. 1995; 30: 609
   PubMed Web of Science ®Google Scholar
• Lindsay K. L., Davis G. L., Bodenheimer H. C., et al. Predictors of relapse and response to re-treatment in patients with an initial response to recombinant alpha interferon (r IFN) therapy for chronic hepatitis C. Hepatology 1990; 12: 847
   Google Scholar
• Cimino L., Nardone G., Citarella C., et al. Treatment of chronic hepatitis C with recombinant interferon alpha. Ital. J. Gastroenterol. 1991; 23: 399
   PubMedGoogle Scholar
• Di Bisceglie A. M., Hoofnagle J. H. Therapy of chronic hepatitis C with alpha interferon:the answer? or more questions?. Hepatology 1991; 13: 601
   Google Scholar
• Weiland O. Interferon therapy in chronic hepatitis C virus infection. FEMS. Microbiol. Rev. 1994; 14: 279
   PubMed Web of Science ®Google Scholar
• Cuthbert J. A., Hepatitis C. progress and problems, Clin. Microbiol. Rev. 1994; 7: 505
   Google Scholar
• Cerny A., Chisari F. V. Immunological aspects of HCV infection. Intervirology 1994; 37: 119
   PubMed Web of Science ®Google Scholar
• Gonzalez-Peralta R. P., Davis G. L., Lav J. Y.N. Pathogenetic mechanism of hepatocellular damage in chronic hepatitis C virus infection. J. Hepatol. 1994; 21: 255
   Google Scholar
• Mauss S., Heintges T., Adams O., et al. Treatment of chronic hepatitis C with interferon-α in patients infected with the human immunodeficiency virus. Hepato-Gastroenterol. 1995; 42: 528
   PubMed Web of Science ®Google Scholar
• Li X., Jeffers L. J., Reddy K. R., et al. lmmunophenotyping of lymphocytes in liver tissue of patients with chronic liver diseases by flow cytometry. Hepatology 1991; 14: 121
   PubMed Web of Science ®Google Scholar
• Sculty L. J., Brown D., Lloyd C., et al. Immunological studies before and during interferon therapy in chronic HBV infection:identification of factors predicting response. Hepatology 1990; 12: 1111
   Google Scholar
• Puppo F., Picciotto A., Brenci S., et al. Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response?. J. Clin. Immunol. 1995; 4: 179
   Google Scholar
• Matsunaga T., Kojima J., Inoue A., et al. Prediction of sustained response to interferon alpha therapy with serum soluble interleukin 2 receptor levels in patients with chronic hepatitis C. Int. Hepatol. Communic. 1995; 3: 173
   Google Scholar
• Saito H., Atsukawa K., Morizane T., et al. Correlation between response to interferon therapy and in vitro antibody production in patients with chronic hepatitis C. Clin. Immunol. Immunop. 1995; 1: 209
   Google Scholar
• Guadagnino V., Caroleo B., Izzi A., et al. T-lymphocyte subpopulations as factors predicting clinical response to interferon in hepatitis C virus-related chronic active hepatitis. Infection 1995; 3: 189
   Google Scholar
• Veno T., Inuzuka S., Sata M., et al. Serum hyaluronate predictis response to interferon-α therapy in patients with chronic hepatitis C. Hepato-Gastroenterol. 1995; 42: 523
   Google Scholar
• Ishibashi K., Kashiwagi T., Ito A., et al. Predictive factors for efficacy of interferon therapy in chronic hepatitis type C. Hepato-Gastroenterol. 1995; 42: 535
   Google Scholar